Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7
01 Noviembre 2023 - 5:00AM
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates against validated molecular targets in indications of
high unmet medical need, today announced that it will host a
Diabetic Cardiomyopathy (DbCM) expert forum with key opinion
leaders on Tuesday, November 7, 2023 at 8:00 a.m. ET.
Members of the Company’s senior management team
will be joined by the following key opinion leaders:
- James Januzzi, MD, Hutter Family
Professor of Medicine, Harvard Medical School; Director, Dennis and
Marilyn Barry Fellowship in Cardiology Research, Massachusetts
General Hospital
- Gregory Lewis, MD, Director,
Cardiopulmonary Exercise Testing Laboratory and Section Head, Heart
Failure, Massachusetts General Hospital
The agenda for the event is as follows:
- Diabetic Cardiomyopathy Disease
Overview & Treatment Landscape (Dr. Januzzi)
- ARISE-HF Registrational Phase 3
Trial Overview (Dr. Januzzi)
- Cardiac Functional Capacity
(primary endpoint in ARISE-HF) (Dr. Lewis)
- Q&A (with Drs. Januzzi and
Lewis as well as Applied Therapeutics management)
The forum will be webcast live. Webcast
information for this event will be accessible on the Events page
under the Investor Relations section of the Applied Therapeutics
website at www.appliedtherapeutics.com. A replay of the webcast
will be archived on the Company’s website following the forum.
About Applied Therapeutics
Applied Therapeutics is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates against
validated molecular targets in indications of high unmet medical
need. The Company’s lead drug candidate, govorestat, is a novel
central nervous system penetrant Aldose Reductase Inhibitor (ARI)
for the treatment of CNS rare metabolic diseases, including
Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also
developing AT-001, a novel potent ARI, for the treatment of
Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart.
The preclinical pipeline also includes AT-003, an ARI designed to
cross through the back of the eye when dosed orally, for the
treatment of Diabetic Retinopathy.
To learn more, please visit www.appliedtherapeutics.com and
follow the company on Twitter @Applied_Tx.
Contacts
Investors:
Maeve Conneighton (212) 600-1902
appliedtherapeutics@argotpartners.com
Media:
media@appliedtherapeutics.com
Applied Therapeutics, Inc.
Applied Therapeutics (NASDAQ:APLT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Applied Therapeutics (NASDAQ:APLT)
Gráfica de Acción Histórica
De May 2023 a May 2024